A Safety Study in Patients With Major Depressive Disorder
| Status: | Archived |
|---|---|
| Conditions: | Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2010 |
| End Date: | August 2012 |
Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
The primary objective of this study is to evaluate the long-term safety and tolerability of
LY2216684 administered once daily (QD) in the adjunctive treatment with a selective
serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in patients with major
depressive disorder (MDD) who are partial responders to their SSRI treatment.
We found this trial at
12
sites
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
New York Methodist Hospital A voluntary, acute-care teaching hospital, New York Methodist Hospital's mission is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials